MedTrace Logo

A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific Countries

NCT01677598 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 169

Last updated 2024-10-28

No results posted yet for this study

Summary

The purpose of this study is to determine how patients use ustekinumab (label-recommended or other/missed dose interval) in Asia-Pacific countries.

Conditions

Interventions

DRUG

No intervention

No intervention will be administered during study. This will be an observational study in patients using ustekinumab as label-recommended or other/missed dose interval in Asia-Pacific countries

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-02
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • Indonesia
  • Malaysia
  • Singapore
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01677598 on ClinicalTrials.gov